{"id":"11c-raclopride","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2104769","moleculeType":"Small molecule","molecularWeight":"346.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"[11C]raclopride is a carbon-11 labeled derivative of raclopride, a selective dopamine D2/D3 receptor antagonist. The radioactive carbon-11 isotope allows real-time visualization of dopamine receptor density and occupancy in vivo using PET imaging. It is primarily used as a research and diagnostic tool to assess dopaminergic neurotransmission in neuropsychiatric and neurodegenerative disorders.","oneSentence":"[11C]raclopride is a radioactive dopamine D2/D3 receptor antagonist used as a positron emission tomography (PET) imaging agent to visualize dopamine receptor binding in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:29.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of dopamine D2/D3 receptor binding in the brain for research and diagnostic purposes"},{"name":"Assessment of dopaminergic dysfunction in Parkinson's disease, schizophrenia, and other neuropsychiatric disorders"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Raclopride, serial number 009"],"phase":"marketed","status":"active","brandName":"[11C]raclopride","genericName":"[11C]raclopride","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"[11C]raclopride is a radioactive dopamine D2/D3 receptor antagonist used as a positron emission tomography (PET) imaging agent to visualize dopamine receptor binding in the brain. Used for PET imaging of dopamine D2/D3 receptor binding in the brain for research and diagnostic purposes, Assessment of dopaminergic dysfunction in Parkinson's disease, schizophrenia, and other neuropsychiatric disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}